東華軟件(002065.SZ):擬對東華醫為合計增資7000萬元
格隆匯6月14日丨東華軟件(002065.SZ)公佈,公司於2021年6月11日召開第七屆董事會第二十五次會議,審議通過了《關於對子公司增資的議案》,同意公司及全資子公司北京東華合創科技有限公司根據各自出資比例以自有資金對控股子公司東華醫為科技有限公司(“東華醫為”)增資人民幣7000萬元。此次增資完成後,東華醫為註冊資本由人民幣1.3億元增至人民幣2億元。
公司此次對東華醫為增資是基於公司戰略發展和經營發展的需要,能夠支持其產業持續發展,進一步提升東華醫為的綜合實力和對外形象,有助於東華醫為更好地實現業務拓展,增強其綜合競爭能力和盈利能力,符合公司長遠發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.